MENU
electroCore LLC

News & Events

June 21, 2017
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy   Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced the appointment of Peter Staats MD, MBA, ABIPP, [...]
June 21, 2017
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth   Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive Officer (CEO), Francis R. Amato, has been elected to [...]
June 15, 2017
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches   Basking Ridge, NJ, June 15, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug [...]
June 08, 2017
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society Basking Ridge, NJ, June 8, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced new data from [...]
April 25, 2017
Data from ACT2 Clinical Trial of gammaCore® in Cluster Headache Presented for First Time Yesterday During Emerging Science Session Basking Ridge, NJ, April 26, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that “Non-invasive Vagus Nerve Stimulation for the Acute Treatment [...]
April 18, 2017
– First U.S. Food and Drug Administration (FDA) release for electroCore, a neuroscience and technology company – Hand-held, non-invasive, easy-to-use device provides new option for the approximately 400,000 Americans living with this rare but extremely debilitating headache disorder Basking Ridge, NJ, April 18, 2017 – electroCore, a neuroscience and technology company dedicated [...]
January 23, 2017
electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those involved in the commissioning of healthcare products or [...]
November 14, 2016
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve stimulation (nVNS) [...]
October 31, 2016
An observational study presented at the at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress has found that non-invasive vagus nerve stimulation is an effective treatment for patients with medically unexplained symptoms. The study also showed that nVNS treatment significantly reduced the total number of [...]
October 20, 2016
Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000. This compares with [...]

OK